Evaluation of Blood Coagulation Parameters and ADMA, NO, IL-6, and IL-18 Serum Levels in Patients with Neovascular AMD before, during, and after the Initial Loading Phase of Intravitreal Aflibercept
We evaluated the effect of intravitreal injections of aflibercept (IVA) on blood coagulation parameters including prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT), as well as asymmetric dimethylarginine (ADMA), nitric oxide (NO), interleukin 6 (IL-6), and i...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/11/5/441 |
| _version_ | 1797534022285393920 |
|---|---|
| author | Michał Wiciński Małgorzata Seredyka-Burduk Sławomir Liberski Daria Marczak Magdalena Pol Bartosz Malinowski Katarzyna Pawlak-Osińska Bartlomiej J. Kaluzny |
| author_facet | Michał Wiciński Małgorzata Seredyka-Burduk Sławomir Liberski Daria Marczak Magdalena Pol Bartosz Malinowski Katarzyna Pawlak-Osińska Bartlomiej J. Kaluzny |
| author_sort | Michał Wiciński |
| collection | DOAJ |
| description | We evaluated the effect of intravitreal injections of aflibercept (IVA) on blood coagulation parameters including prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT), as well as asymmetric dimethylarginine (ADMA), nitric oxide (NO), interleukin 6 (IL-6), and interleukin 18 (IL-18) serum levels in patients with neovascular AMD (nAMD). Twenty-two eyes of 22 patients with nAMD were included. Parameters were evaluated before and 2–3 days after the first IVA injection, and then immediately before and 2–3 days after the third IVA injection. We revealed prolongation of the TT after the initial loading phase of IVA (<i>p</i> = 0.041) and a significant increase in IL-18 serum concentration immediately before the third IVA administration compared to baseline (<i>p</i> = 0.037). There were no statistically significant differences of other parameters and PT, APTT, ADMA, NO, and IL-6 values remained within the normal range at each of the time points of the study. Our results suggest that repeated IVA administration may affect the common blood coagulation pathway, which manifests as a prolongation of the TT value. Furthermore, we showed a significant increase in serum concentration of the pro-inflammatory cytokineIL-18during the initial loading phase of IVA. |
| first_indexed | 2024-03-10T11:23:47Z |
| format | Article |
| id | doaj.art-438c84ef8a1e43218d7ff93cf5d25035 |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-10T11:23:47Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-438c84ef8a1e43218d7ff93cf5d250352023-11-21T19:47:46ZengMDPI AGLife2075-17292021-05-0111544110.3390/life11050441Evaluation of Blood Coagulation Parameters and ADMA, NO, IL-6, and IL-18 Serum Levels in Patients with Neovascular AMD before, during, and after the Initial Loading Phase of Intravitreal AfliberceptMichał Wiciński0Małgorzata Seredyka-Burduk1Sławomir Liberski2Daria Marczak3Magdalena Pol4Bartosz Malinowski5Katarzyna Pawlak-Osińska6Bartlomiej J. Kaluzny7Department of Pharmacology and Therapeutics, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, M. Curie 9, 85-090 Bydgoszcz, PolandDivision of Ophthalmology and Optometry, Department of Ophthalmology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, M. Curie 9, 85-090 Bydgoszcz, PolandDepartment of Pharmacology and Therapeutics, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, M. Curie 9, 85-090 Bydgoszcz, PolandDepartment of Pharmacology and Therapeutics, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, M. Curie 9, 85-090 Bydgoszcz, PolandDivision of Ophthalmology and Optometry, Department of Ophthalmology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, M. Curie 9, 85-090 Bydgoszcz, PolandDepartment of Pharmacology and Therapeutics, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, M. Curie 9, 85-090 Bydgoszcz, PolandDivision of Human Anatomy and Physiology, Institute of Health Sciences, Pomeranian University of Słupsk, K. Arciszewskiego 22A, 76-200 Słupsk, PolandDivision of Ophthalmology and Optometry, Department of Ophthalmology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, M. Curie 9, 85-090 Bydgoszcz, PolandWe evaluated the effect of intravitreal injections of aflibercept (IVA) on blood coagulation parameters including prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT), as well as asymmetric dimethylarginine (ADMA), nitric oxide (NO), interleukin 6 (IL-6), and interleukin 18 (IL-18) serum levels in patients with neovascular AMD (nAMD). Twenty-two eyes of 22 patients with nAMD were included. Parameters were evaluated before and 2–3 days after the first IVA injection, and then immediately before and 2–3 days after the third IVA injection. We revealed prolongation of the TT after the initial loading phase of IVA (<i>p</i> = 0.041) and a significant increase in IL-18 serum concentration immediately before the third IVA administration compared to baseline (<i>p</i> = 0.037). There were no statistically significant differences of other parameters and PT, APTT, ADMA, NO, and IL-6 values remained within the normal range at each of the time points of the study. Our results suggest that repeated IVA administration may affect the common blood coagulation pathway, which manifests as a prolongation of the TT value. Furthermore, we showed a significant increase in serum concentration of the pro-inflammatory cytokineIL-18during the initial loading phase of IVA.https://www.mdpi.com/2075-1729/11/5/441afliberceptage-related macular degenerationanti-VEGFasymmetric dimethylargininecoagulation parametersinterleukin 6 |
| spellingShingle | Michał Wiciński Małgorzata Seredyka-Burduk Sławomir Liberski Daria Marczak Magdalena Pol Bartosz Malinowski Katarzyna Pawlak-Osińska Bartlomiej J. Kaluzny Evaluation of Blood Coagulation Parameters and ADMA, NO, IL-6, and IL-18 Serum Levels in Patients with Neovascular AMD before, during, and after the Initial Loading Phase of Intravitreal Aflibercept Life aflibercept age-related macular degeneration anti-VEGF asymmetric dimethylarginine coagulation parameters interleukin 6 |
| title | Evaluation of Blood Coagulation Parameters and ADMA, NO, IL-6, and IL-18 Serum Levels in Patients with Neovascular AMD before, during, and after the Initial Loading Phase of Intravitreal Aflibercept |
| title_full | Evaluation of Blood Coagulation Parameters and ADMA, NO, IL-6, and IL-18 Serum Levels in Patients with Neovascular AMD before, during, and after the Initial Loading Phase of Intravitreal Aflibercept |
| title_fullStr | Evaluation of Blood Coagulation Parameters and ADMA, NO, IL-6, and IL-18 Serum Levels in Patients with Neovascular AMD before, during, and after the Initial Loading Phase of Intravitreal Aflibercept |
| title_full_unstemmed | Evaluation of Blood Coagulation Parameters and ADMA, NO, IL-6, and IL-18 Serum Levels in Patients with Neovascular AMD before, during, and after the Initial Loading Phase of Intravitreal Aflibercept |
| title_short | Evaluation of Blood Coagulation Parameters and ADMA, NO, IL-6, and IL-18 Serum Levels in Patients with Neovascular AMD before, during, and after the Initial Loading Phase of Intravitreal Aflibercept |
| title_sort | evaluation of blood coagulation parameters and adma no il 6 and il 18 serum levels in patients with neovascular amd before during and after the initial loading phase of intravitreal aflibercept |
| topic | aflibercept age-related macular degeneration anti-VEGF asymmetric dimethylarginine coagulation parameters interleukin 6 |
| url | https://www.mdpi.com/2075-1729/11/5/441 |
| work_keys_str_mv | AT michałwicinski evaluationofbloodcoagulationparametersandadmanoil6andil18serumlevelsinpatientswithneovascularamdbeforeduringandaftertheinitialloadingphaseofintravitrealaflibercept AT małgorzataseredykaburduk evaluationofbloodcoagulationparametersandadmanoil6andil18serumlevelsinpatientswithneovascularamdbeforeduringandaftertheinitialloadingphaseofintravitrealaflibercept AT sławomirliberski evaluationofbloodcoagulationparametersandadmanoil6andil18serumlevelsinpatientswithneovascularamdbeforeduringandaftertheinitialloadingphaseofintravitrealaflibercept AT dariamarczak evaluationofbloodcoagulationparametersandadmanoil6andil18serumlevelsinpatientswithneovascularamdbeforeduringandaftertheinitialloadingphaseofintravitrealaflibercept AT magdalenapol evaluationofbloodcoagulationparametersandadmanoil6andil18serumlevelsinpatientswithneovascularamdbeforeduringandaftertheinitialloadingphaseofintravitrealaflibercept AT bartoszmalinowski evaluationofbloodcoagulationparametersandadmanoil6andil18serumlevelsinpatientswithneovascularamdbeforeduringandaftertheinitialloadingphaseofintravitrealaflibercept AT katarzynapawlakosinska evaluationofbloodcoagulationparametersandadmanoil6andil18serumlevelsinpatientswithneovascularamdbeforeduringandaftertheinitialloadingphaseofintravitrealaflibercept AT bartlomiejjkaluzny evaluationofbloodcoagulationparametersandadmanoil6andil18serumlevelsinpatientswithneovascularamdbeforeduringandaftertheinitialloadingphaseofintravitrealaflibercept |